An activating KIT mutation induces crizotinib resistance in ROS1 positive lung cancer

INTRODUCTION: Non-small cell lung cancer (NSCLC) patients with ROS1 chromosomal rearrangements benefit from treatment with the ROS1 inhibitor crizotinib. Limited data exist on the spectrum of resistance mechanisms in ROS1+ NSCLC. To delineate mechanisms of acquired resistance, we analyzed tumor samp...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Thorac Oncol
Huvudupphovsmän: Dziadziuszko, Rafal, Le BA, Anh T., Wrona, Anna, Jassem, Jacek, Camidge, D. Ross, Varella-Garcia, Marileila, Aisner, Dara L., Doebele, Robert C.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2016
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4961521/
https://ncbi.nlm.nih.gov/pubmed/27068398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2016.04.001
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk